SCHEMBL3402295

SCHEMBL3402295

Cc1nc(-c2cccc(OC(F)(F)F)c2)sc1C(=O)N1CCN(C2CCCC2)CC1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.46
SLC6A7 Q99884 1/20 0.43
MCHR1 Q99705 1/20 0.43
ALDH1A1 P00352 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
HTR2C P28335 5/20 0.42
THRA P10827 2/20 0.42
THRB P10828 2/20 0.42
MAPK1 P28482 1/20 0.42
HPGD P15428 1/20 0.41
MEN1 O00255 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
LMNA P02545 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
CCKAR P32238 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13309673 0.92 HRH3 (0.50) CNR1ALDH1A1SMN1; SMN2HTR2CTHRA
SCHEMBL3404798 0.92 HRH3 (0.50) CNR1ALDH1A1SMN1; SMN2HTR2CTHRA
SCHEMBL3398454 0.90 MAPK1 (0.51) CNR1ALDH1A1SMN1; SMN2HTR2CTHRA
SCHEMBL3402224 0.89 HRH3 (0.48) CNR1ALDH1A1SMN1; SMN2HTR2CTHRA
SCHEMBL3400211 0.87 CNR1 (0.48) CNR1ALDH1A1SMN1; SMN2HTR2CTHRA
SCHEMBL3401081 0.86 LMNA (0.47) CNR1ALDH1A1SMN1; SMN2HTR2CTHRA
SCHEMBL3404145 0.86 ALDH1A1 (0.60) CNR1ALDH1A1SMN1; SMN2HTR2CTHRA
SCHEMBL3398926 0.85 TRPM8 (0.54) CNR1ALDH1A1SMN1; SMN2HTR2CTHRA
SCHEMBL3404795 0.85 CNR1 (0.53) CNR1ALDH1A1SMN1; SMN2HTR2CTHRA
SCHEMBL3404671 0.84 CNR1 (0.48) CNR1SLC6A7ALDH1A1SMN1; SMN2HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues LIGAND PHARMACEUTICALS, INC. (US) 2010-11-25 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
WO-2006089076-A9 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORP (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues HRH3, HRH4, HRH2 CNR1 35/4885SLC6A7 493/4885MCHR1 366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.